Professional
Added to YB: 2025-10-22
Pitch date: 2025-09-30
NTLA [neutral]
Intellia Therapeutics, Inc.
-28.83%
current return
Author Info
No bio for this author
Company Info
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
Market Cap
$2.0B
Pitch Price
$17.38
Price Target
N/A
Dividend
N/A
EV/EBITDA
-4.35
P/E
-3.98
EV/Sales
22.97
Sector
Biotechnology
Category
growth
Contrarius Global Equity Fund Portfolio Holding: Intellia Therapeutics, Inc.
NTLA (holding update): Leading in-vivo CRISPR with 2 Phase 3 trials for ATTR-CM & hereditary angioedema. One-shot treatments vs competitors' ongoing therapies offer superior patient compliance & economics. High gross margins expected. ATTR market est. $12B by FY28 - even small share material for $2B market cap co.
Read full article (2 min)